MarketCapExport financials
Viveve Medical (VIVE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Viveve Medical Cash Flow 2021-2009 | VIVE
Brief overview of Viveve Medical's cash movements
Cash flow changes are traced through the five latest available reports from 2017 to 2021.
Cash from operations is below zero at -$12.9 million, increasing dependence on cash reserves or outside financing.
Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.
About $3.3 million was released from working capital. The benefit supports cash flow but may be temporary.
What the cash flows show
Viveve Medical's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.
Annual Cash Flow Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-12.9 M | -15.2 M | -31.2 M | -43.1 M | -34.9 M | -18.1 M | -12.2 M | -5.99 M | -3.76 M | -3.16 M | -3.6 M | -2.78 M | - |
Depreciation & Amortization |
1.12 M | 1.3 M | 1.18 M | 786 K | 449 K | 111 K | 77 K | 56 K | 66 K | 43 K | 9 K | 42 K | - |
Accounts Payables |
1.48 M | 881 K | 1.61 M | 3.99 M | 4.8 M | 3.09 M | 1.43 M | 416 K | 967 K | 377 K | 149 K | 343 K | - |
Accounts Receivables |
549 K | 770 K | 1.57 M | 5.7 M | 6.21 M | 2.09 M | 593 K | 6 K | 502 K | 402 K | 453 K | 121 K | - |
Total Inventories |
1.47 M | 3.25 M | 4.86 M | 4.12 M | 2.39 M | 2.69 M | 1.55 M | 131 K | 228 K | 182 K | 238 K | 310 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -13 M | -9.66 M | -5.09 M | - | -9.65 M | -6.99 M | -3.25 M | - | -12.9 M | -10.2 M | -5.74 M | - | -6.61 M | -7.7 M | -11.6 M | - | -33.2 M | -23.2 M | -15.2 M | - | -26.3 M | -17.3 M | -8.05 M | - | -12.2 M | -6.3 M | -2.05 M | - | -8.33 M | -5.07 M | -1.67 M | - | -4.05 M | -1.18 M | -631 K | - | -2.95 M | -2.87 M | -2.16 M | - | - | - | -949 K | - | -2.98 M | -2.12 M | -915 K |
Depreciation & Amortization |
- | 568 K | 392 K | 204 K | - | 884 K | 636 K | 328 K | - | 965 K | 651 K | 323 K | - | 819 K | 547 K | 311 K | - | 545 K | 334 K | 150 K | - | 318 K | 188 K | 107 K | - | 78 K | 45 K | 21 K | - | 57 K | 36 K | 17 K | - | 42.2 K | 24 K | 13 K | - | 39 K | 26 K | 13 K | - | 31 K | 20 K | 8 K | - | 3 K | 4 K | 2 K |
Accounts Payables |
- | 1.11 M | 904 K | 1.6 M | 1.48 M | 1.29 M | 662 K | 1.16 M | 881 K | 695 K | 1.26 M | 2.26 M | 1.61 M | 1.79 M | 1.61 M | 2.69 M | 3.99 M | 3.56 M | 4.87 M | 3.86 M | 4.8 M | 3.57 M | 3.34 M | 3.36 M | 3.09 M | 2.48 M | 1.85 M | 1.63 M | 1.43 M | 1.1 M | 612 K | 612 K | 416 K | 566 K | 775 K | 510 K | 967 K | 443 K | 432 K | 340 K | 377 K | 231 K | 417 K | 130 K | 149 K | 39 K | 48 K | 149 K |
Accounts Receivables |
- | 860 K | 801 K | 509 K | 549 K | 514 K | 696 K | 336 K | 770 K | 689 K | 1.02 M | 1.28 M | 1.57 M | 2.81 M | 3.56 M | 4.78 M | 5.7 M | 4.99 M | 7.24 M | 7 M | 6.21 M | 4.83 M | 3.8 M | 4.02 M | 2.09 M | 1.81 M | 589 K | 791 K | 593 K | 239 K | 6 K | 35 K | 6 K | 3.75 K | 361 K | 257 K | 502 K | 488 K | 210 K | 374 K | 402 K | 525 K | 352 K | 308 K | 453 K | 237 K | 263 K | 453 K |
Total Inventories |
- | 1.62 M | 1.6 M | 1.55 M | 1.47 M | 2.15 M | 2.63 M | 3.05 M | 3.25 M | 4.59 M | 4.92 M | 4.46 M | 4.86 M | 4.14 M | 4.71 M | 3.87 M | 4.12 M | 4.5 M | 4.16 M | 3.83 M | 2.39 M | 1.9 M | 2.04 M | 2.38 M | 2.69 M | 1.41 M | 845 K | 926 K | 1.55 M | 645 K | 337 K | 167 K | 131 K | 137 K | 101 K | 112 K | 228 K | 145 K | 161 K | 89 K | 182 K | 235 K | 200 K | 219 K | 238 K | 200 K | 154 K | 238 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Viveve Medical, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B |  USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Zynex
ZYXI
|
- | - | $ 21.1 M | USA |
 |
Abiomed
ABMD
|
- | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
Butterfly Network
BFLY
|
$ 6.5 | -2.1 % | $ 1.61 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
Invacare Corporation
IVC
|
- | - | $ 24.7 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.45 | -1.97 % | $ 616 M |  Israel |
 |
Beyond Air
XAIR
|
$ 2.52 | 10.34 % | $ 20.9 B | USA |
 |
Alphatec Holdings
ATEC
|
$ 6.99 | -5.35 % | $ 1.05 B | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 388.54 | 0.06 % | $ 10.6 B | USA |
 |
Aethlon Medical
AEMD
|
$ 5.53 | 0.73 % | $ 3.73 M | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 0.34 % | $ 121 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.19 | -1.94 % | $ 1.99 B |  Costa-rica |
 |
Delcath Systems
DCTH
|
$ 20.08 | -0.96 % | $ 719 M | USA |
 |
Electromed
ELMD
|
$ 27.2 | 1.29 % | $ 225 M | USA |
 |
Inogen
INGN
|
$ 6.02 | -1.64 % | $ 160 M | USA |
 |
Globus Medical
GMED
|
$ 75.35 | -1.34 % | $ 10.2 B | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.87 | -0.08 % | $ 1.11 B | USA |
 |
ClearPoint Neuro
CLPT
|
$ 8.79 | -4.2 % | $ 249 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 3.17 | -17.02 % | $ 389 M | USA |
 |
AxoGen
AXGN
|
$ 50.89 | 0.49 % | $ 2.34 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.7 | -0.41 % | $ 11.9 M | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 5.81 | -0.34 % | $ 362 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 14.54 | 1.18 % | $ 1.11 B | USA |
 |
Bruker Corporation
BRKR
|
$ 62.25 | -5.4 % | $ 9.45 B | USA |
 |
LivaNova PLC
LIVN
|
$ 91.39 | -1.32 % | $ 4.99 B | Britain |
|
LENSAR
LNSR
|
$ 4.97 | -8.97 % | $ 59.4 M | USA |
 |
Orthofix Medical
OFIX
|
$ 7.12 | -9.94 % | $ 282 M |  Curacao |
 |
Pulmonx Corporation
LUNG
|
$ 2.81 | 0.18 % | $ 114 M | USA |
 |
InspireMD
NSPR
|
$ 0.78 | 9.49 % | $ 50.2 M | Israel |
 |
InMode Ltd.
INMD
|
$ 13.26 | -1.89 % | $ 857 M | Israel |
 |
OrthoPediatrics Corp.
KIDS
|
$ 33.43 | -1.65 % | $ 784 M | USA |
 |
Outset Medical
OM
|
$ 4.22 | 2.43 % | $ 64.2 M | USA |
 |
PAVmed
PAVM
|
$ 1.64 | 0.31 % | $ 1.1 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.56 | 4.36 % | $ 4.33 M | USA |
 |
AVITA Medical
RCEL
|
$ 17.62 | 2.92 % | $ 491 M |  Australia |
 |
Tandem Diabetes Care
TNDM
|
$ 18.7 | 2.92 % | $ 1.27 B | USA |